A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group

Endocrine and Neuroendocrine Tumors (NET)

Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study

Lancet Oncol

Xing M, Lin S, Mathur A, Li Y, Bendlova B, Kuklikova V, Melo M, Jesus TT, Soares P, Colombo C, Fugazzola L, Mitsutake N, Matsuse M, Sako A, Estrada-Florez AP, Carvajal-Carmona LG, Bohórquez ME, Mian C, Vianello F, O'Neill CJ, Clifton-Bligh R, Czarniecka A, Jarzab B, Jung CK, Brahma B, Ladenson PW, Park YJ

doi: 10.1016/S1470-2045(25)00399-7

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Lung Cancer

Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R

doi: 10.1016/j.lungcan.2025.108797

Lung, Respiratory and Thoracic Cancer

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Transl Lung Cancer Res

Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L

doi: 10.21037/tlcr-24-881

Central Nervous System Tumors

Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant Glioma

Neuro Oncol

Youssef G, Aquilanti E, Miller JJ, Lan Z, Lasica AB, Arrillaga-Romany I, Batchelor TT, Berger TR, Beroukhim R, Chukwueke U, Dietrich J, Forst DA, Gerstner ER, Castro LNG, Jordan JT, Mcfaline-Figueroa JR, Lee EQ, Nayak L, Nakhate V, Ospina JP, Plotkin SR, Wang N, Rhee JY, Reardon DA, Wen PY

doi: 10.1093/neuonc/noaf287

Leukemia

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study

Leukemia

Gurnari C, Makishima H, Durmaz A, Attardi E, Saiki R, Bataller A, Sapinho G, Gondek L, Nannya Y, Best S, Krishnamurthy P, Kong KL, Atsuta Y, Kasahara S, Ohyashiki K, Miyazaki Y, Kanemura N, Hiramoto N, Versino F, Montoro MJ, Torres-Esquius S, Jerez Cayuela A, López-Esteban M, Martínez-Laperche C, Awada H, Visconte V, DiNardo CD, Voso MT, DeZern AE, Garcia-Manero G, Kulasekararaj AG, Maciejewski JP, Ogawa S

doi: 10.1038/s41375-025-02814-0

Genitourinary Cancer

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study

Eur Urol

Karpinski MJ, Rahbar K, Bögemann M, Nikoukar LR, Schäfers M, Hoberück S, Miederer M, Hölscher T, Rasul S, Miszczyk M, Lanfranchi F, Bauckneht M, Pfob CH, Kind F, Goffin K, Hüsing A, Kesch C, Herrmann K, Stuschke M, Gafita A, Hüsing J, Calais J, Hofman MS, Hope TA, Miksch J, Soeterik TFW, Di Giorgio A, Farolfi A, Bjartell A, Trägårdh E, Unterrainer LM, Holzgreve A, Sheikh GT, Rauscher I, Eiber M, Hadaschik BA, Fendler WP

doi: 10.1016/j.eururo.2025.04.017

Lung, Respiratory and Thoracic Cancer

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

Lancet Oncol

Di Federico A, Wang K, Chen MF, Barsouk AA, Pagliaro A, Chen LN, Ogliari FR, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton GM, Citarella F, Meyer D, Aldea M, De Giglio A, Alessi JV, Pecci F, Gelsomino F, Corassa M, Vokes NI, Wang X, de Biase D, Abu Rous F, Areesawangkit P, Elghawy O, Cortellini A, Metro G, Ferrara R, Awad MM, Pabani A, Murray JC, Cappuzzo F, Garassino MC, Dagogo-Jack I, Riely G, Grant M, Herzberg BO, Ardizzoni A, Planchard D, Johnson BE, Langer CJ, Offin M, Negrao MV, Ricciuti B

doi: 10.1016/S1470-2045(25)00409-7

Skin Cancer

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Lancet Oncol

Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D

doi: 10.1016/S1470-2045(25)00139-1

Leukemia

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy

Br J Haematol

Konuma T, Shimomura Y, Mizuno S, Yamasaki S, Yui S, Uchida N, Doki N, Tanaka M, Yoshihara S, Eto T, Katayama Y, Katsuoka Y, Tokunaga M, Ota S, Sakata-Yanagimoto M, Ishiwata K, Kanda Y, Kawakita T, Onizuka M, Kanda J, Fukuda T, Atsuta Y, Yanada M

doi: 10.1111/bjh.20208

Related content

Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study

Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant Glioma

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF(V600E)-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantation and Cellular Therapy